140 related articles for article (PubMed ID: 36174408)
1. Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: A single-center study.
Karimi N; Fatehi F; Okhovat AA; Abdi S; Sinaei F; Sikaroodi H; Vahabi Z; Nafissi S
Clin Neurol Neurosurg; 2022 Nov; 222():107441. PubMed ID: 36174408
[TBL] [Abstract][Full Text] [Related]
2. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
[TBL] [Abstract][Full Text] [Related]
6. Myasthenia gravis and COVID-19: A case series and comparison with literature.
Saied Z; Rachdi A; Thamlaoui S; Nabli F; Jeridi C; Baffoun N; Kaddour C; Belal S; Ben Sassi S
Acta Neurol Scand; 2021 Sep; 144(3):334-340. PubMed ID: 33914898
[TBL] [Abstract][Full Text] [Related]
7. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.
Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M
Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
9. Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.
Abbas AS; Hardy N; Ghozy S; Dibas M; Paranjape G; Evanson KW; Reierson NL; Cowie K; Kamrowski S; Schmidt S; Tang Y; Davis AR; Touchette JC; Kallmes KM; Hassan AE; Tarchand R; Mehta M; Pederson JM; Abdelmegeed M
Clin Neurol Neurosurg; 2022 Feb; 213():107140. PubMed ID: 35091255
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
[TBL] [Abstract][Full Text] [Related]
11. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
[TBL] [Abstract][Full Text] [Related]
12. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
[TBL] [Abstract][Full Text] [Related]
13. Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19.
Gungor Tuncer O; Deymeer F
Muscle Nerve; 2022 Apr; 65(4):447-452. PubMed ID: 35040147
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.
Rodrigues CL; de Freitas HC; Lima PRO; de Oliveira Junior PH; Fernandes JMA; D'Almeida JAC; Nóbrega PR
Neurol Sci; 2022 Apr; 43(4):2271-2276. PubMed ID: 35039987
[TBL] [Abstract][Full Text] [Related]
15. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C; Stascheit F; Eckert C; Pawlitzki M; Schroeter CB; Huntemann N; Mergenthaler P; Arat E; Öztürk M; Foell D; Schreiber S; Vielhaber S; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Meuth SG; Meisel A; Wiendl H; Ruck T
J Neuroinflammation; 2022 Apr; 19(1):89. PubMed ID: 35413850
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
Gajdos P; Chevret S
Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report.
Neykova KK; Milanova M; Ignatov PN
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):8308-8316. PubMed ID: 34582289
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
Furlan JC; Barth D; Barnett C; Bril V
Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
[TBL] [Abstract][Full Text] [Related]
20. IVIG and PLEX in the treatment of myasthenia gravis.
Bril V; Barnett-Tapia C; Barth D; Katzberg HD
Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
